Study of ERBB2 and EGFR in Gastric Cancer
Author Information
Author(s): YK Wang, CF Gao, T Yun, Z Chen, XW Zhang, XX Lv, NL Meng, WZ Zhao
Primary Institution: The 150 Centre Hospital of Chinese PLA, Medical Center of Jinan Military Region, Luoyang, China
Hypothesis
The study aims to investigate the amplification and expression of ERBB2 and EGFR genes in gastric cancer.
Conclusion
ERBB2 and EGFR genetic abnormalities are associated with the prognosis of gastric cancer.
Supporting Evidence
- 20.3% of gastric cancer cases exhibited ERBB2 gene amplification.
- 29.0% of samples showed EGFR gene amplification.
- ERBB2 and EGFR gene amplification were significantly associated with tumor invasion and lymph node metastasis.
Takeaway
This study looked at how certain genes related to cancer behave in stomach cancer, finding that changes in these genes can help doctors decide on treatments.
Methodology
Fluorescence in situ hybridization (FISH) and immunohistochemistry were used to analyze ERBB2 and EGFR gene amplification and protein expression.
Participant Demographics
Patients included 69 gastric cancer patients with an average age of 59.2 years.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website